Schiff Hardin advised The Benchmark Company as managing underwriter in the transaction
The shareholders of the dermatology-focused biotechnology company have pre-emptive rights under German law and Biofrontera’s shares already traded on the Frankfurt Stock Exchange, making this a very complex transaction. The transaction involved side-by-side U.S. and German pre-emptive rights offerings.
Biofrontera AG operates as a biopharmaceutical company. The Company, led by Hermann Luebbert, Thomas Schaffer and Christoph Duenwald, develops, sales, and distributes dermatological drugs and medical cosmetics.
Schiff Hardin advised The Benchmark Company with a team including Ralph V. De Martino (Picture), F. Alec Orudjev and Cavas S. Pavri.
Law Firms: Schiff Hardin LLP;
Clients: The Benchmark Company;